Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tucidinostat + azacitidine + cyclophosphamide + epirubicin + vindesine + prednisone
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous, Intravenous
01
Overview
Tucidinostat + azacitidine + cyclophosphamide + epirubicin + vindesine + prednisone (also referred to as AC-CHOP in clinical trial contexts) is an experimental combination regimen being evaluated for the first-line treatment of peripheral T-cell lymphoma (PTCL). The regimen combines two epigenetic modulators—tucidinostat (a subtype-selective HDAC inhibitor targeting HDAC1, 2, 3, and 10) and azacitidine (a DNA methyltransferase inhibitor)—with a modified CHOP chemotherapy backbone. This approach is based on the premise that epigenetic priming with HDAC inhibitors and hypomethylating agents can sensitize T-cell lymphoma cells to conventional cytotoxic chemotherapy. Peking Union Medical College Hospital is the lead sponsor for a Phase III trial investigating this combination's efficacy and safety compared to standard CHOP in untreated patients.
- Other names
- tucidinostat + azacitidine + CHOPchidamide + azacitidine + CHOPHBI-8000 + azacitidine + CHOP
02
Targets
HDAC10 (Histone Deacetylase 10)HDAC1 (Histone Deacetylase 1)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNADNMT1 (DNA (cytosine-5)-methyltransferase 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on tucidinostat + azacitidine + cyclophosphamide + epirubicin + vindesine + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tucidinostat + azacitidine + cyclophosphamide + epirubicin + vindesine + prednisone.